All In Biotech

Drug Trial Radar · NCT02333071

1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder

Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

Last checked: Nov 19, 2026Latest source record: Apr 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 723 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

723

Actual

Start

Dec 2014

Primary completion

Jul 2016

Study completion Jun 30, 2017

Sponsor

Lead sponsor
Palatin Technologies, IncIndustry
Sponsor type
Industry
First posted
Jan 7, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females.

Conditions

  • Hypoactive Sexual Desire Disorder

Interventions

  • BremelanotideDrug

    A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)

  • PlaceboOther

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall.Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)
  2. Efficacy of a Fixed Dose of Bremelanotide as Measured by FSDS-DAO (Item 13)Time frame: 8 weeks baseline plus 24 weeks (Main Study), 52 Weeks (OLE)

Locations

91 sites in 2 countries. Site status is shown where the registry gives one.

  • Palatin Clinical Site 121

    Birmingham, Alabama

  • Palatin Clinical Site 110

    Huntsville, Alabama

  • Palatin Clinical Site 106

    Mobile, Alabama

  • Palatin Clinical Site 149

    Scottsdale, Arizona

  • Palatin Clinical Site 157

    Tucson, Arizona

  • Palatin Clinical Site 166

    Little Rock, Arkansas

  • Palatin Clinical Site 102

    National City, California

  • Palatin Clinical Site 164

    Oceanside, California

  • Palatin Clinical Site 152

    Orange, California

  • Palatin Clinical Site 188

    Sacramento, California

  • Palatin Clinical Site 141

    San Diego, California

  • Palatin Clinical Site 187

    Walnut Creek, California

  • Palatin Clinical Site 160

    Centennial, Colorado

  • Palatin Clinical Site 185

    Colorado Springs, Colorado

  • Palatin Clinical Site 130

    Bradenton, Florida

  • Palatin Clinical Site 128

    Hollywood, Florida

  • Palatin Clinical Site 134

    Jacksonville, Florida

  • Palatin Clinical Site 108

    Melbourne, Florida

  • Palatin Clinical Site 105

    Orlando, Florida

  • Palatin Clinical Site 131

    South Miami, Florida

  • Palatin Clinical Site 144

    St. Petersburg, Florida

  • Palatin Clinical Site 101

    West Palm Beach, Florida

  • Palatin Clinical Site 116

    Decatur, Georgia

  • Palatin Clinical Site 142

    Savannah, Georgia

  • Palatin Clinical Site 171

    Meridian, Idaho

  • Palatin Clinical Site 179

    Evansville, Indiana

  • Palatin Clinical Site 165

    Lafayette, Indiana

  • Palatin Clinical Site 154

    Mishawaka, Indiana

  • Palatin Clinical Site 184

    West Des Moines, Iowa

  • Palatin Clinical Site 155

    Overland Park, Kansas

  • Palatin Clinical Site 104

    Wichita, Kansas

  • Palatin Clinical Site 191

    Louisville, Kentucky

  • Palatin Clinical Site 194

    Eunice, Louisiana

  • Palatin Clinical Site 186

    New Orleans, Louisiana

  • Palatin Clinical Site 183

    Bangor, Maine

  • Palatin Clinical Site 159

    Annapolis, Maryland

  • Palatin Clinical Site 119

    Boston, Massachusetts

  • Palatin Clinical Site 126

    Watertown, Massachusetts

  • Palatin Clinical Site 163

    Bingham Farms, Michigan

  • Palatin Clinical Site 181

    Rochester, Michigan

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.